Targeting histone deacetylases for heart failure
Background: Stresses such as chronic hypertension and myocardial infarction can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies suggest key roles for his...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on therapeutic targets 2009-07, Vol.13 (7), p.767-784 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 784 |
|---|---|
| container_issue | 7 |
| container_start_page | 767 |
| container_title | Expert opinion on therapeutic targets |
| container_volume | 13 |
| creator | Bush, Erik W McKinsey, Timothy A |
| description | Background: Stresses such as chronic hypertension and myocardial infarction can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies suggest key roles for histone deacetylases (HDACs) in the control of pathological cardiac remodeling. Objective/methods: Here, we review these target validation experiments and highlight non-cardiac functions of HDACs that will need to be addressed during development of HDAC-directed therapies for heart failure. Results/conclusions: HDACs are unique and attractive therapeutic targets for heart failure because of their positions far downstream in pathological signaling cascades. Confirmation of the validity and viability of approaches aimed at HDACs awaits in vivo proof-of-concept testing with novel small molecule regulators of these enzymes. |
| doi_str_mv | 10.1517/14728220902939161 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_19466913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746087365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-ed0cabf471a8bb4b5c86fc3d3f8334f9a91ce85903372480ae93d64e5e1e21fa3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBfZk55Wk0022aAXKX5BwUs9h9nspN2y3a3JLtJ_b6QFEaGnGZjnfRkeQi4ZvWU5U3dMqKzIMqppprlmkh2RMVNCpEpydhz3eE8jkI3IWQgrSiOay1MyYlpIqRkfEzoHv8C-bhfJsg5912JSIVjstw0EDInrfLJE8H3ioG4Gj-fkxEET8GI_J-Tj-Wk-fU1n7y9v08dZagWXfYoVtVA6oRgUZSnK3BbSWV5xV3AunAbNLBa5ppyrTBQUUPNKCsyRYcYc8Am52fVufPc5YOjNug4WmwZa7IZglJC0UFzmkbw-SErFC02FjCDbgdZ3IXh0ZuPrNfitYdT8CDX_hMbM1b58KNdY_Sb2BiPwsAPqNrpaw1fnm8r0sG067zy0tg6GH-q__xOPrpt-acGjWXWDb6PiA999AzmVlRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67389046</pqid></control><display><type>article</type><title>Targeting histone deacetylases for heart failure</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Bush, Erik W ; McKinsey, Timothy A</creator><creatorcontrib>Bush, Erik W ; McKinsey, Timothy A</creatorcontrib><description>Background: Stresses such as chronic hypertension and myocardial infarction can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies suggest key roles for histone deacetylases (HDACs) in the control of pathological cardiac remodeling. Objective/methods: Here, we review these target validation experiments and highlight non-cardiac functions of HDACs that will need to be addressed during development of HDAC-directed therapies for heart failure. Results/conclusions: HDACs are unique and attractive therapeutic targets for heart failure because of their positions far downstream in pathological signaling cascades. Confirmation of the validity and viability of approaches aimed at HDACs awaits in vivo proof-of-concept testing with novel small molecule regulators of these enzymes.</description><identifier>ISSN: 1472-8222</identifier><identifier>EISSN: 1744-7631</identifier><identifier>DOI: 10.1517/14728220902939161</identifier><identifier>PMID: 19466913</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Animals ; Cardiomegaly - drug therapy ; Cardiomegaly - physiopathology ; chromatin ; Drug Delivery Systems ; Drug Design ; Enzyme Inhibitors - pharmacology ; heart failure ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; histone deacetylase ; Histone Deacetylase Inhibitors ; Histone Deacetylases - metabolism ; Humans ; hypertrophy ; signaling ; Ventricular Remodeling - drug effects</subject><ispartof>Expert opinion on therapeutic targets, 2009-07, Vol.13 (7), p.767-784</ispartof><rights>Informa UK Ltd 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-ed0cabf471a8bb4b5c86fc3d3f8334f9a91ce85903372480ae93d64e5e1e21fa3</citedby><cites>FETCH-LOGICAL-c436t-ed0cabf471a8bb4b5c86fc3d3f8334f9a91ce85903372480ae93d64e5e1e21fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/14728220902939161$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/14728220902939161$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,59646,59752,60435,60541</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19466913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bush, Erik W</creatorcontrib><creatorcontrib>McKinsey, Timothy A</creatorcontrib><title>Targeting histone deacetylases for heart failure</title><title>Expert opinion on therapeutic targets</title><addtitle>Expert Opin Ther Targets</addtitle><description>Background: Stresses such as chronic hypertension and myocardial infarction can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies suggest key roles for histone deacetylases (HDACs) in the control of pathological cardiac remodeling. Objective/methods: Here, we review these target validation experiments and highlight non-cardiac functions of HDACs that will need to be addressed during development of HDAC-directed therapies for heart failure. Results/conclusions: HDACs are unique and attractive therapeutic targets for heart failure because of their positions far downstream in pathological signaling cascades. Confirmation of the validity and viability of approaches aimed at HDACs awaits in vivo proof-of-concept testing with novel small molecule regulators of these enzymes.</description><subject>Animals</subject><subject>Cardiomegaly - drug therapy</subject><subject>Cardiomegaly - physiopathology</subject><subject>chromatin</subject><subject>Drug Delivery Systems</subject><subject>Drug Design</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>histone deacetylase</subject><subject>Histone Deacetylase Inhibitors</subject><subject>Histone Deacetylases - metabolism</subject><subject>Humans</subject><subject>hypertrophy</subject><subject>signaling</subject><subject>Ventricular Remodeling - drug effects</subject><issn>1472-8222</issn><issn>1744-7631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlZ_gBfZk55Wk0022aAXKX5BwUs9h9nspN2y3a3JLtJ_b6QFEaGnGZjnfRkeQi4ZvWU5U3dMqKzIMqppprlmkh2RMVNCpEpydhz3eE8jkI3IWQgrSiOay1MyYlpIqRkfEzoHv8C-bhfJsg5912JSIVjstw0EDInrfLJE8H3ioG4Gj-fkxEET8GI_J-Tj-Wk-fU1n7y9v08dZagWXfYoVtVA6oRgUZSnK3BbSWV5xV3AunAbNLBa5ppyrTBQUUPNKCsyRYcYc8Am52fVufPc5YOjNug4WmwZa7IZglJC0UFzmkbw-SErFC02FjCDbgdZ3IXh0ZuPrNfitYdT8CDX_hMbM1b58KNdY_Sb2BiPwsAPqNrpaw1fnm8r0sG067zy0tg6GH-q__xOPrpt-acGjWXWDb6PiA999AzmVlRk</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Bush, Erik W</creator><creator>McKinsey, Timothy A</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>20090701</creationdate><title>Targeting histone deacetylases for heart failure</title><author>Bush, Erik W ; McKinsey, Timothy A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-ed0cabf471a8bb4b5c86fc3d3f8334f9a91ce85903372480ae93d64e5e1e21fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Cardiomegaly - drug therapy</topic><topic>Cardiomegaly - physiopathology</topic><topic>chromatin</topic><topic>Drug Delivery Systems</topic><topic>Drug Design</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>histone deacetylase</topic><topic>Histone Deacetylase Inhibitors</topic><topic>Histone Deacetylases - metabolism</topic><topic>Humans</topic><topic>hypertrophy</topic><topic>signaling</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bush, Erik W</creatorcontrib><creatorcontrib>McKinsey, Timothy A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Expert opinion on therapeutic targets</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bush, Erik W</au><au>McKinsey, Timothy A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting histone deacetylases for heart failure</atitle><jtitle>Expert opinion on therapeutic targets</jtitle><addtitle>Expert Opin Ther Targets</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>13</volume><issue>7</issue><spage>767</spage><epage>784</epage><pages>767-784</pages><issn>1472-8222</issn><eissn>1744-7631</eissn><abstract>Background: Stresses such as chronic hypertension and myocardial infarction can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies suggest key roles for histone deacetylases (HDACs) in the control of pathological cardiac remodeling. Objective/methods: Here, we review these target validation experiments and highlight non-cardiac functions of HDACs that will need to be addressed during development of HDAC-directed therapies for heart failure. Results/conclusions: HDACs are unique and attractive therapeutic targets for heart failure because of their positions far downstream in pathological signaling cascades. Confirmation of the validity and viability of approaches aimed at HDACs awaits in vivo proof-of-concept testing with novel small molecule regulators of these enzymes.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19466913</pmid><doi>10.1517/14728220902939161</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-8222 |
| ispartof | Expert opinion on therapeutic targets, 2009-07, Vol.13 (7), p.767-784 |
| issn | 1472-8222 1744-7631 |
| language | eng |
| recordid | cdi_pubmed_primary_19466913 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Animals Cardiomegaly - drug therapy Cardiomegaly - physiopathology chromatin Drug Delivery Systems Drug Design Enzyme Inhibitors - pharmacology heart failure Heart Failure - drug therapy Heart Failure - physiopathology histone deacetylase Histone Deacetylase Inhibitors Histone Deacetylases - metabolism Humans hypertrophy signaling Ventricular Remodeling - drug effects |
| title | Targeting histone deacetylases for heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A30%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20histone%20deacetylases%20for%20heart%20failure&rft.jtitle=Expert%20opinion%20on%20therapeutic%20targets&rft.au=Bush,%20Erik%20W&rft.date=2009-07-01&rft.volume=13&rft.issue=7&rft.spage=767&rft.epage=784&rft.pages=767-784&rft.issn=1472-8222&rft.eissn=1744-7631&rft_id=info:doi/10.1517/14728220902939161&rft_dat=%3Cproquest_pubme%3E746087365%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67389046&rft_id=info:pmid/19466913&rfr_iscdi=true |